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Fanconi anemia (FA) is a rare genetically heterogeneous disorder associated 
with bone marrow failure, birth defects and cancer susceptibility. Apart from the disease-
causing mutations in FANC genes, the identification of specific DNA variations, such as 
single nucleotide polymorphisms (SNPs), in other candidate genes may lead to a better 
clinical description of this condition enabling individualized treatment with 
improvement of the prognosis. In this study, we have assessed 95 SNPs located in 52 
key genes involved in base excision repair (BER), nucleotide excision repair (NER), 
mismatch repair (MMR), double strand break (DSB) repair and cell cycle control using a 
DNA repair chip (Asper Biotech, Estonia) which includes most of the common variants 
for the candidate genes. The SNP genotyping was performed in five FA-D2 patients and 
in one FA-A patient. The polymorphisms studied were synonymous (n=10), 
nonsynonymous (missense) (n=52) and in non-coding regions of the genome (introns 
and 5 ‘and 3’ untranslated regions (UTR)) (n=33). Polymorphisms found at the 
homozygous state are selected for further analysis. Our results have shown a significant 
inter-individual variability among patients in the type and the frequency of SNPs and 
also elucidate the need for further studies of polymorphisms located in ATM, APEX APE 
1, XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, CDKN1B, TP53 and TP53BP1  
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which may be of great importance for better clinical description of FA.  In addition, the 
present report recommends the use of SNPs as predictive and prognostic genetic markers 
to individualize therapy of FA patients. 
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List of abbreviations 
APEX APE1- APEX nuclease (multifunctional DNA repair enzyme) 1; ATM- ataxia telangiectasia 
mutated serine/threonine kinase; BRCA1- breast cancer 1, early onset; BARD1- BRCA1 
associated RING domain 1; BRCA2- breast cancer 2, early onset; BER- base excision repair; 
CCND1- cyclin D1; CCNH- cyclin H; p21/CDKN1A-  cyclin-dependent kinase inhibitor 1A (p21, 
Cip1);  CDKN2A- cyclin-dependent kinase inhibitor 2A ; CDKN1B- cyclin-dependent kinase 
inhibitor 1B (p27, Kip1); CDK7-  cyclin-dependent kinase 7; CHEK2-  checkpoint kinase 2;  
DSB- double strand break; ERCC1- excision repair cross-complementation group 1; ERCC2- 
excision repair cross-complementation group 2; ERCC4- excision repair cross-complementation 
group 4; ERCC5- excision repair cross-complementation group 5; FANCD2- Fanconi anemia, 
complementation group D2; GADD45A- growth arrest and DNA-damage-inducible, alpha; 
GRTH/Ddx25-  DEAD (Asp-Glu-Ala-Asp) box helicase 25; LIG1- ligase I, DNA, ATP-
dependent; LIG3- ligase III, DNA, ATP-dependent; LIG4-  ligase IV, DNA, ATP-dependent; 
MGMT AGT- O-6-methylguanine-DNA methyltransferase; MLH1- mutL homolog 1; MMR- 
mismatch repair; MSH2- mutS homolog 2; MSH3- mutS homolog 3; MSH6- mutS homolog 6; 
MYH- mutY DNA glycosylase; NER- nucleotide excision repair; NBS1- nibrin; OGG1- 8-
oxoguanine DNA glycosylase; PARP1- poly (ADP-ribose) polymerase 1; PARP4- poly (ADP-
ribose) polymerase family, member 4; PCNA- proliferating cell nuclear antigen; PMS2- PMS2 
postmeiotic segregation increased 2 (S. cerevisiae); POLB- polymerase (DNA directed), beta; 
RAD9A-  RAD9 checkpoint clamp component A ; RAD23B- RAD23 homolog B (S. cerevisiae); 
RAD51- RAD51 recombinase; RAD52- RAD52 homolog (S. cerevisiae); RAD54B- RAD54 
homolog B (S. cerevisiae); RECQL- RecQ helicase-like; XPA- xeroderma pigmentosum, 
complementation group A; XPC- xeroderma pigmentosum, complementation group C; XRCC1- 
X-ray repair complementing defective repair in Chinese hamster cells 1; XRCC2- X-ray repair 
complementing defective repair in Chinese hamster cells 2; XRCC3- X-ray repair complementing 
defective repair in Chinese hamster cells 3; XRCC4- X-ray repair complementing defective repair 
in Chinese hamster cells 4; XRCC5- X-ray repair complementing defective repair in Chinese 
hamster cells 5 (double-strand-break rejoining); XRCC9/FANCG- Fanconi anemia, 
complementation group G; SNP- single nucleotide polymorphism; TP53- tumor protein p53; 
TP53BP1- tumor protein p53 binding protein 1; TP53BP2- tumor protein p53 binding protein 2 
 
INTRODUCTION 
Fanconi anemia (FA) is a recessive disorder considered to encompass a defect in 
maintenance of genome integrity. It is associated with bone marrow failure, birth defects and 
predisposition to cancer. The disease is genetically heterogeneous with 16 complementation 
groups (FA -A to FA –Q) and associated genes having been characterized (KEE and D'ANDREA, 
2012; BOGLIOLO et al., 2013; CHEN et al., 2014). All of the 16 gene products operate in a common 
process to maintain genome stability. Some of these proteins have extranuclear activities affecting 
redox balance, apoptosis and energy metabolism (CAPPELLI et al., 2013). The most frequent 
complementation group is FA-A (~ 60% of all cases of the disease); FA-C and FA-G account for 
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~ 10-15% of the cases while the rest of the cases (~ 15%) is distributed over the remaining 
complementation groups (e.g. the prevalence of FA-D2 is 3.3%) (MAGDALENA et al., 2005; 
MATHEW, 2006; AMEZIANE et al., 2012). Regardless of the complementation group, FA is a 
condition involving high risk of leukemia and solid tumors (KUTLER et al., 2003).  However, FA 
patients exhibit a high degree of clinical variability and have poor tolerance for radiotherapy and 
chemotherapy (MATHEW, 2006). Thus, the knowledge of factors that might predict either the 
best drug response or adverse outcome would greatly facilitate the decision making concerning 
the choices of treatment.  
Single nucleotide polymorphisms (SNPs) represent one of the largest types of inherited 
genetic variations (BOND and LEVINE, 2007) and are considered as predictive and prognostic 
genetic markers.  Polymorphisms in DNA repair and cell cycle control genes may alter protein 
function leading to genomic instability and increased cancer risk (SIGURDSON et al., 2004).  
As already known, Fanconi anemia is a disease associated with deficiencies in DNA 
repair pathway, which may be the cause of the overall increased cancer risk in patients.  FA 
proteins constitute the FA pathway responsible for repair of inter - and intra - strand DNA cross - 
links either occurring spontaneously or induced by clastogens as mitomycin C or diepoxybutane 
(JOENJE and PATEL, 2001; KIM and D'ANDREA, 2012). However, apart from the disease-causing 
mutations in FANC genes, the identification of specific variations in other candidate genes in FA 
patients may lead to a better clinical description of this condition enabling individualized 
treatment with improvement of the prognosis. In light of the fact that Fanconi anemia is a highly 
penetrant cancer susceptibility disorder, the products of the identified genes could become targets 
for innovative therapies in patients. In addition, the genotyping of SNPs in key genes involved in 
DNA repair may provide insight into the interactions between FA mutation and specific 
variations in DNA repair genes in each of the FA patients.  
The results presented here focus on assessment of the known variations located in genes 
involved in base excision repair (BER), nucleotide excision repair (NER), mismatch repair 
(MMR), double strand break (DSB) repair and also in the several genes related to the cell cycle 
control and apoptosis. Investigation was performed in patients belonging to complementation 
groups FA-A and FA-D2; the last one present as the most prevalent complementation group in 
Serbia.  
 
MATERIALS AND METHODS 
Patients 
Six patients aged 3 to 13 years who had previously been diagnosed with FA based on clinical 
features were enrolled in this study. All of the patients had several developmental malformations 
(skin, skeletal, genitourinary and neurological anomalies) and developed bone marrow failure at 
an early age. At the moment of sampling, no one of the patients has been diagnosed with cancer.  
A clinical diagnosis of FA was confirmed by a positive diepoxybutane (DEB) test (AUERBACH, 
1993). Complementation group assignment was performed by immunoblotting at the Department 
of Genetics Microbiology, Universitat Autonoma de Barcelona, Spain, and at Universität 
Würzburg, Institut für Humangenetik, Germany. The FA complementation group analysis showed 
that five patients belong to the complementation group FA-D2 (Patients #1 - #5), whereas only 
one patient belongs to the complementation group FA-A (Patient #6). Informed consent for 
investigation was obtained from all families, and the study was approved by the Ethical 
Committee of the Mother and Child Health Care Institute of Serbia.  
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DNA isolation 
DNA was isolated from patients-derived fibroblasts using the phenol-chloroform method. The 
cells were treated with STE buffer (10 mM TRIS-HCl, 100 mM NaCl, 1 mM EDTA), proteinase 
K (10 mg/mL) (Sigma-Aldrich) and 10% SDS (sodium dodecyl sulfate) (Sigma-Aldrich) and 
incubated for 2 hours at 55 ºC. Afterwards, the upper layer (250 - 300 µL) was transferred to a 
new tube, and dH2O (50 µL) and phenol (Sigma-Aldrich) (300 µL) were added. The suspension 
was vigorously vortexed and then centrifuged for 10 minutes at 12000 rpm in a microcentrifuge. 
The supernatant (250 - 300 µL) was placed into a new tube and chloroform (~150 µL) (Sigma-
Aldrich) was added. After centrifugation for 10 minutes at 12000 rpm, the supernatant (250 - 300 
µL) was transferred to a new tube and treated with 7.5 M ammonium acetate (150 µL) and ice-
cold 100% ethanol (1.5 mL). After centrifugation for 5 minutes at 12000 rpm, the supernatant was 
decanted and the pellet was air-dried for 1-2 minutes and re-suspended  in  appropriate volume 
dH2O (30-50 µL). The quantification of the concentration and purity of the DNA was performed 
using a spectrophotometer (Nanodrop-1000, Thermo Fisher Scientific, USA). 
Single nucleotide polymorphism analysis 
For SNP analysis, DNA samples (concentration 1 µg/µL at least) were studied using DNA repair 
chip which includes most of the common variants for the DNA repair genes as well as for the 
several genes related to the cell cycle control and apoptosis. The SNP genotyping was performed 
at the Asper Biotech (Tartu, Estonia) (http://www.asperbio.com/DNArepairchip.pdf). The total 
number of SNPs analyzed in this cohort is 95, and the total number of genes is 52. 
 
RESULTS  
In this study, we have assessed 95 SNPs located in 52 key genes involved in BER, NER, 
MMR, DSB repair and cell cycle control using an Asper Biotech array. The investigation was 
performed in five FA-D2 patients and in one FA-A patient. The summary of genes involved in 
different repair and cell cycle control pathways and corresponding SNPs are presented in Tables 1 
- 2. Some genes are involved in more than one pathway, but each is listed only once. All of the 
SNPs studied are accessible at the NCBI (National Center for Biotechnology Information) 
database (http://www.ncbi.nlm.nih.gov/snp). 
The polymorphisms studied were synonymous (n=10), nonsynonymous (missense) 
(n=52) and in non-coding regions of the genome (introns and 5 ‘and 3’ untranslated regions 
(UTR)) (n=33). Polymorphisms found at the homozygous state (genotypes in bold, see Tables 1-
2) are selected for further analysis. 
In the BER pathway, the SNPs located in APEX, LIG1, LIG3, MYH, OGG1, PARP1, 
PCNA, POLB and XRCC1 were evaluated. As shown in Table 1, the most of the studied 
polymorphisms were found as heterozygous variants, while the homozygous variants were found 
in APEX APE1, LIG1, LIG3 and PARP1. The missense variation was found in APEX APE1 
(rs3136820) (p.Asp148Glu) in patients #2 and #5. In LIG1, an intronic variation (rs3730849) was 
found in patients #3 and #5, while the intronic rs1805403 of PARP1 was detected in patients #3, 
#4 and #6. The 3`-UTR rs1052536 of LIG3 was found in patients #5 and #6.  
In the NER pathway, we analyzed polymorphisms located in ERCC1, ERCC2 (XPD), 
ERCC4 (FANCQ), ERCC5 (XPG), GADD45A, RAD23B, XPA and XPC (Table 1). The 
homozygous missense variation rs13181 (p.Lys751Gln) of ERCC2 was found in patient #3. The 
intronic rs3212948 of ERCC1 was detected in patients #1, #2, #4 and #5. In GADD45A, an 
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intronic rs532446 was detected in patients #1 and #2, while the 5`-UTR variant rs1800975 of 
XPA was detected in patients #1, #2 and #5.  
 
Table 1. Summary of DNA repair genes screened for polymorphisms 
 
 
 
 Detected polymorphisms in FA patients 
Gene 
Gene 
location 
dbSNP 
(rs#) 
Position 
in gene 
Nucl. 
chan
ge 
Pat # 1 Pat # 2 Pat # 3 Pat # 4 Pat # 5 Pat # 6 
Base excision repair (BER) 
APEX APE1 14q11.2-q12 rs10489 Exon 3 G/C G/C G/C G/ G/C G/C G/C 
rs31368 Exon 5 T/G T/A G/C T/ TG/AC G/C TG/AC 
LIG1 
19q13.2-
q13. 
rs20579 Exon 2 C/T CT/GA C/G C/ C/G C/G C/G 
rs37308 Intron 2 C/T CT/GA CT/GA T/ CT/GA T/A C/G 
rs49870 Exon 13 G/A G/C G/C A G/C G/C G/C 
rs37309 Intron 9 A/G AG/TC A/T A/ A/T A/T A/T 
LIG3 17q11.2- rs10525 3`-UTR C/T C/G CT/GA CT CT/GA T/A T/A 
MYH 1p34.3- rs32194 Exon 12 G/C G/C GC/CG G/ G/C GC/CG G/C 
OGG1 3p26.2 rs10521 Exon 7 C/G CG/GC C/G C/ CG/GC CG/GC CG/GC 
PARP 1 1q41-q42 rs11364 Exon 17 T/C T/A T/A T/ T/A T/A T/A 
rs18054 Intron 4 A/G GA/CT GA/CT G/ G/C GA/CT G/C 
PCNA 20pter-p12 rs25406 Intron 2 C/T C/G CT/GA CT C/G C/G CT/GA 
POLB 8p11.2 rs31367 Exon 12 C/G C/G C/G C/ C/G CG/GC C/G 
rs23071 5`-UTR A/G A/T A/T A/ A/T A/T A/T 
XRCC1 19q13.2 
rs17997 Exon 6 C/T CT/GA CT/GA CT C/G C/G C/G 
rs25489 Exon 9 G/A G/C G/C G/ G/C G/C G/C 
rs25487 Exon 10 G/A G/C GA/CT G GA/CT G/C GA/CT 
Direct reversal of damage 
MGMT AGT 10q26 
rs1803965 Exon 5 C/T C/G CT/GA C/G C/G C/G C/G 
rs12917 Exon 5 C/T C/G CT/GA C/G C/G C/G C/G 
rs2308321 Exon 7 A/G AG/TC A/T A/T A/T AG/TC A/T 
Nucleotide excision repair (NER) 
ERCC1 19q13.2-q13.3 
rs3212948 Intron 3 G/C C/ C/G GC/CG C/G C/G GC/CG 
rs11615 Exon 4 T/C T/ T/A TC/AG T/A T/A TC/AG 
rs3212961 Intron 5 C/A C/ C/G CA/GT C/G C/G CA/GT 
rs3212986 3`-UTR G/T G/ G/C G/C G/C G/C GT/CA 
ERCC2 
(XPD) 
19q13.3 rs13181 Exon 23 A/C A/ A/T C/G A/T AC/TG AC/TG 
rs238406 Exon 6 C/A CA CA/GT C/G C/G CA/GT C/G 
ERCC4/FA 16p13.12 rs1800067 Exon 8 G/A G G/C G/C GA/CT G/C GA/CT 
ERCC5 
XPG 
13q33 rs1047768 Exon 2 T/C TC T/A TC/AG TC/AG T/A TC/AG 
rs17655 Exon 15 G/C G/ G/C GC/CG GC/CG GC/CG GC/CG 
GADD45A 1p31.2-p31.1 rs532446 Intron 3 T/C C/ C/G T/A T/A TC/AG T/A 
RAD23B 9q31.2 rs1805329 Exon 7 C/T CT C/G CT/GA C/G C/G C/G 
XPA 9q22.3 rs1800975 5`-UTR A/G G/ G/C GA/CT GA/CT G/C GA/CT 
XPC 3p25 rs2228001 Exon 16 C/A AC C/G C/G C/G AC/TG C/G 
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Table 1 Continued 
 Detected polymorphisms in FA patients 
Gene 
Gene 
location 
dbSNP 
(rs#) 
Position 
in gene 
Nucl. 
chan
ge 
Pat # 1 
Pat # 
2 
Pat # 3 Pat # 4 Pat # 5 Pat # 6 
Mismatch repair (MMR) 
MLH1 3p21.3 rs1799977 Exon 8 A/G AG/TC AG/T AG/TC AG/TC A/T AG/TC 
MSH2 2p22-p21 rs4987188 Exon 6 G/A G/C G/C G/C G/C G/C G/C 
MSH3 5q11-q12 rs184967 Exon 21 A/G GA/CT G/C GA/CT GA/CT G/C GA/CT 
rs26279 Exon 23 G/A AG/TC AG/T G/C G/C A/T G/C 
MSH6 2p16 rs1800935 Exon 3 T/C T/A CT/G T/A T/A T/A C/G 
PMS2 7p22.2 rs1805324 Exon 11 G/A G/C G/C G/C G/C G/C GA/CT 
RECQL 12p12 rs13035 3`-UTR A/C AC/TG AC/T AC/TG A/T A/T A/T 
Double strand break (DSB) repair 
BARD1     2q34-q35 rs2070094 Exon 6 G/A A/T G/C GA/CT GA/CT G/C A/T 
rs2070093 Exon 6 T/C C/G C/G C/G CT/GA CT/GA C/G 
BRCA1    17q21 
rs799917 
Exon 10 
C/T CT/GA C/G CT/GA CT/GA CT/GA C/G 
rs4986850 G/A G/C G/C G/C G/C G/C G/C 
rs16941 A/G AG/TC A/T AG/TC AG/TC AG/TC A/T 
rs4986852 G/A G/C GA/C G/C G/C G/C G/C 
rs1799950 A/G A/T A/T A/T A/T AG/TC A/T 
BRCA2/ 
FANCD1 
  13q12.3 
rs1799943 5`-UTR G/A GA/CT A/T GA/CT G/C G/C GA/CT 
rs144848 Exon 10 A/C A/T A/T A/T A/T A/T A/T 
rs4987117 Exon 11 C/T C/G C/G CT/GA C/G C/G C/G 
rs15869 3`-UTR A/C A/T A/T AC/TG AC/TG A/T AC/TG 
FANCD2   3p26 rs3732974 5`-UTR C/G G/C G/C G/C G/C G/C G/C 
LIG4    13q33-q34 rs1805388 Exon 2 C/T CT/GA C/G C/G CT/GA CT/GA CT/GA 
rs1805389 Exon 2 C/T CT/GA C/G C/G C/G CT/GA C/G 
NBS1     8q21 rs1063045 Exon 2 G/A G/C G/C GA/CT A/T G/C G/C 
rs1805794 Exon 6 G/C G/C G/C GC/CG C/G G/C G/C 
PARP 4 
    13q11 
rs1050112 Exon 31 C/A C/G CA/G C/G C/G A/T C/G 
rs13428 Exon 31 G/C G/C CG/G G/C G/C C/G G/C 
rs4986817 Exon 21 A/T A/T A/T A/T A/T A/T A/T 
rs4986819 Intron 19 C/G C/G C/G C/G C/G C/G C/G 
rs7571 Exon 33 G/C G/C CG/G G/C G/C C/G G/C 
RAD51    15q15.1 rs1801320 5`-UTR G/C G/C G/C GC/CG GC/CG G/C G/C 
RAD52    12p13- rs11226 3`-UTR C/T C/G C/G CT/GA T/A CT/GA CT/GA 
RAD54B    8q21.3- rs2291439 Exon 5 T/C C/G TC/A TC/AG TC/AG T/A TC/AG 
XRCC2   7q36.1 rs3218536 Exon 3 G/A GA/CT G/C G/C G/C G/C G/C 
rs718282 3`-UTR C/T C/G C/G C/G C/G C/G C/G 
XRCC3  14q32.3 
rs861539 Exon 8 C/T CT/GA CT/G CT/GA C/G C/G C/G 
rs1799796 Intron 7 A/G AG/TC AG/T AG/TC AG/TC G/C A/T 
rs1799794 5`-UTR A/G A/T A/T A/T A/T A/T A/T 
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In the MMR pathway, the SNPs located in MLH1, MSH2, MSH3, MSH6, PMS2 and 
RECQL were evaluated. The homozygous missense variants rs184967 (p.Gln949Arg) and 
rs26279 (p.Ala1045Thr) of MSH3 were found in patients #2 and #5, and patient #5, respectively. 
The synonymous rs1800935 of MSH6 was detected in patient #6. 
In the DSB repair pathway, which consists of both homologous recombination and non-
homologous end-joining, SNPs located in BRCA1, BRCA2 (FANCD1), FANCD2, LIG4, NBS1, 
PARP4, RAD51, RAD52, RAD54B, XRCC2, XRCC3, XRCC4, XRCC5 and XRCC9 (FANCG) 
were investigated (Table 1).  Similar to the results obtained analyzing the BER, NER and MMR 
pathways explained above, the most of the nucleotide changes were at the heterozygous state. The 
Table 1 Continued 
 Detected polymorphisms in FA patients 
Gene Gen dbSNP Position Nucl. Pat # 1 Pat # Pat # 3 Pat # 4 Pat # 5 Pat # 6 
XRCC4 5q13 rs180537 Intron 7 G/A G/C GA/C A/T G/C G/C G/C 
XRCC5 2q35 rs105167 3`-UTR T/C TC/AG T/A T/A T/A T/A T/A 
rs2440 G/A G/C GA/C G/C GA/CT GA/CT G/C 
XRCC9/FANCG 9p13 rs223785 Exon 7 C/T C/G C/G C/G C/G C/G C/G 
 Detected polymorphisms in FA patients  
Gene Gene 
location 
dbSNP (rs#) Position 
in gene 
Nucl. 
change 
Pat # 1 Pat # 2 Pat # 3 Pat # 4 Pat # 5 Pat # 6 
ATM 11q22-q23 
rs664677 Intron 20 T/C TC/A T/A TC/A TC/A C/G TC/A
rs1800057 Exon 22 C/G C/G CG/G C/G C/G C/G C/G 
rs1801516 Exon 37 G/A G/C G/C G/C G/C G/C GA/C
rs1801673 Exon 37 A/T G/C G/C G/C G/C G/C GA/C
rs609429 Intron 46 C/G CG/G C/G CG/G CG/G G/C CG/G
CCND1 11q13 rs603965 Exon 4 G/A GA/C GA/C A/T GA/C GA/C GA/C
rs678653 3`-UTR C/G G/C GC/C G/C GC/C GC/C GC/C
CCNH 5q13.3-q14 rs2266690 Exon 7 T/C TC/A T/A T/A T/A TC/A TC/A
p21/CDKN1A 6p21.2 rs1801270 Exon 2 C/A C/G CA/G C/G CA/G C/G C/G 
CDKN2A 9p21 rs3731249 Exon 2 G/A G/C G/C G/C G/C G/C G/C 
rs11515 3`-UTR C/G CG/G C/G C/G C/G C/G C/G 
rs3088440 3`-UTR C/T C/G CT/G C/G C/G C/G C/G 
CDKN1B 12p13.1-p12 rs34330 Exon 1 T/C CT/G C/G CT/G CT/G T/A C/G 
CDK7 5q12.1 - rs nr Exon 10 C/T C/G C/G C/G C/G C/G C/G 
CHEK2 22q12.1 - rs nr Exon 13 C/del 1 C/G C/G C/G C/G C/G C/G 
GRTH/Ddx25 11q24 rs551373 Intron 6 G/T G/C G/C G/C G/C G/C G/C 
rs683155 Exon 10 T/C C/G CT/G CT/G T/A CT/G C/G 
RAD9A 11q13.1- rs1064876 3`-UTR G/A G/C G/C G/C G/C G/C G/C 
TP53 17p13.1 rs1042522 Exon 4 C/G GC/C GC/C GC/C G/C G/C GC/C
TP53BP1 15q15-q21 rs560191 Exon 9 C/G CG/G CG/G G/C C/G C/G CG/G
rs689647 Exon 11 G/A GA/C G/C G/C G/C G/C GA/C
TP53BP2 1q42.1 rs17739 3`-UTR G/A G/C G/C GA/C GA/C G/C GA/C
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homozygous variants were found in BARD 1, NBS1, PARP4, RAD54B, RAD52, FANCD2 and 
XRCC4. The missense rs2070094 (p.Val507Met) of BARD 1 was detected in patients #1 and #6. 
The rs1805794 (p.Glu185Gln) of NBS1 was detected in patient #4. The rs1050112 
(p.Pro1328Thr) and rs13428 (p.Gly1280Arg) of PARP4 were found in patient #5. The same 
patient also carried the rs7571 (p.Ala1656Pro) located in the same gene. Of the synonymous 
polymorphisms investigated, the rs2070093 of BARD1 was found in patients #1, #2, #3 and #6. 
The rs1063045 of NBS1 was found in patient #4, while the rs2291439 of RAD54B was found in 
patient #1. Considering the polymorphisms located in the non-coding regions, the 5`-UTR 
rs1799943 of BRCA2 was found in patient #2. The 5`-UTR rs3732974 located in FANCD2 was 
found in all of the patients. The 3`-UTR rs11226 located in RAD52 was found in patient #4. The 
intronic rs1799796 of XRCC3 was found in patient #5, while the intronic rs1805377 of XRCC4 
was found in patient #3. 
Table 2. Summary of cell cycle control genes screened for polymorphisms 
  
 
Results of the analysis of SNPs located in the genes involved in cell cycle control and 
apoptosis are presented in Table 2. We assessed polymorphisms located in ATM, CCND1, CCNH, 
p21/CDKN1A, CDKN2A, CDKN1B, CDK7, CHEK2, GRTH/Ddx25, RAD9A, TP53, TP53BP1 
and TP53BP2. The homozygous variants were found in ATM, CDKN1B, TP53, TP53BP1, 
CCND1 and GRTH/Ddx25.  The missense polymorphism rs34330 (p.Leu332Pro) of CDKN1B 
was detected in patients #2 and #6. The rs1042522 (p.Pro72Arg) of TP53 was found in patients 
#4 and #5. The rs560191 (p.Asp353Glu) of TP53BP1 was found in patient #3. The synonymous 
rs603965 located in CCND1 was detected in patient #3, while the rs683155 of GRTH/Ddx25 was 
found in patients #1 and #6. In addition, the intronic variant rs664677 of ATM was identified in 
patient #5, while the 3`-UTR rs678653 located in CCND1 was found in patients #1 and #3. 
Considering the missense nucleotide substitutions in all of the studied genes, we have 
observed that among the 52 analyzed SNPs, the 29 (~56%) were identified in our patients as 
heterozygous variants, while the 12 of them (~23%) were detected as homozygous variants. Of 
the 10 synonymous SNPs, the six (60%) were found in our patients at the homozygous state. In 
CCNH 5q13.3-q14 rs2266690 Exon 7 T/C TC/A T/A T/A T/A TC/A TC/A
p21/CDKN1A 6p21.2 rs1801270 Exon 2 C/A C/G CA/G C/G CA/G C/G C/G 
CDKN2A 9p21 rs3731249 Exon 2 G/A G/C G/C G/C G/C G/C G/C 
rs11515 3`-UTR C/G CG/G C/G C/G C/G C/G C/G 
rs3088440 3`-UTR C/T C/G CT/G C/G C/G C/G C/G 
CDKN1B 12p13.1-p12 rs34330 Exon 1 T/C CT/G C/G CT/G CT/G T/A C/G 
CDK7 5q12.1 - rs nr Exon 10 C/T C/G C/G C/G C/G C/G C/G 
CHEK2 22q12.1 - rs nr Exon 13 C/del 1 C/G C/G C/G C/G C/G C/G 
GRTH/Ddx25 11q24 rs551373 Intron 6 G/T G/C G/C G/C G/C G/C G/C 
rs683155 Exon 10 T/C C/G CT/G CT/G T/A CT/G C/G 
RAD9A 11q13.1- rs1064876 3`-UTR G/A G/C G/C G/C G/C G/C G/C 
TP53 17p13.1 rs1042522 Exon 4 C/G GC/C GC/C GC/C G/C G/C GC/C
TP53BP1 15q15-q21 rs560191 Exon 9 C/G CG/G CG/G G/C C/G C/G CG/G
rs689647 Exon 11 G/A GA/C G/C G/C G/C G/C GA/C
TP53BP2 1q42.1 rs17739 3`-UTR G/A G/C G/C GA/C GA/C G/C GA/C
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view of the 33 SNPs located in the non-coding regions of selected genes, the thirteen (~40%) of 
them were identified in some of our patients as homozygous variants.  
Summarizing the results presented above it could be seen that SNPs identified at the 
homozygous state were not equally distributed among the patients. Patient #1 carried one 
missense, three synonymous and five polymorphisms in the non-coding region of the genes. 
Patient #2 carried three missense, one synonymous and five substitutions in the non-coding 
regions. Patient #3 carried two missense, two synonymous and five substitutions in the non-
coding regions of the genes. Patient #4 carried two missense, one synonymous and four 
polymorphisms in the non-coding regions. Patient #5 carried seven missense variations, seven 
variations in the non-coding regions of the genes and no one homozygous synonymous 
substitution.  Finally, patient #6 carried two missense variations, three synonymous and three 
variations in the non-coding regions of selected genes. 
Taken together, the results of our investigation have shown a significant inter-individual 
variability among patients in the type and the frequency of SNPs.  
Extensive analysis of the genotype–phenotype correlations in this cohort was not 
possible because of the small number of patients.  
 
DISCUSSION 
This study was aimed at defining the factors that might influence a DNA repair capacity 
in FA patients, which may allow for a more rational therapeutic approach. Accumulating 
evidence suggests that reduced repair capacity is a polymorphic phenotypic trait associated with 
an increased risk of developing tumors at several sites, including breast, lung, skin, liver, or 
head/neck (BERWICK and VINEIS, 2000; MOHRENWEISER et al., 2002). Therefore, the data of the 
factors of the integrity of DNA repair pathways may be used not only in the development of novel 
therapeutic agents but also for the understanding of  the high degree of phenotypic and clinical 
heterogeneity in Fanconi anemia which is in evident contrast with the uniform cellular phenotype 
(HODSON and WALDEN, 2013).   
 In this study, we have genotyped the known polymorphisms located in the DNA repair 
and cell cycle control genes in  FA patients and observed that most of the polymorphisms are 
present at the heterozygous state. Considering the polymorphisms with functional consequences 
i.e., missense polymorphisms, it is possible that heterozygous nucleotide changes in the genes of 
interest could also have various biological and/or pathophysiological effects on FA patients.  
Recent report of Alsbeih and coworkers (ALSBEIH et al., 2013) has shown that radiation toxicity in 
radiotherapy patients is associated with polymorphisms rs1801516 of ATM and rs25487 of 
XRCC1. Results of that study suggest that the presence of protective alleles (ATM rs1801516 A 
and XRCC1 rs25487 A) at the heterozygous status would increase patients’ follow-up after 
radiotherapy by 51 months, while homozygous status would raise this index by 77 months. In our 
cohort, all of the FA-D2 patients were homozygote carriers of the ATM G allele. These results are 
in concordance with our previous investigations reporting the marked radiosensitivity of FA 
patients (LESKOVAC et al., 2010; JOKSIC et al., 2012; LESKOVAC et al., 2014) and support the use 
of SNPs in candidate genes as predictive markers of patients’ radiosensitivity.   
In the BER pathway, the homozygous missense nucleotide changes (rs3136820) were 
found in the APEX. This endonuclease recognizes and begins the process of removing abasic sites 
in DNA (WILSON and THOMPSON, 1997). It has been reported that 148Glu polymorphism does not 
reduce endonuclease activity but it is associated with increased mitotic delay after exposure to 
704                                                                                                             GENETIKA, Vol. 47, No.2,695-710, 2015 
ionizing radiation and an increased risk of colorectal cancer (HU et al., 2001; KASAHARA et al., 
2008). Our previous investigations have shown that exposure to ionizing radiation in vitro 
significantly slowed down the proliferation of FANCD2 fibroblasts compared to control 
fibroblasts (JOKSIC et al., 2012; LESKOVAC et al., 2014). 
In the NER pathway, we detected the homozygous missense polymorphism rs13181 
(p.Lys751Gln) of ERCC2 which is associated with a risk of acute myeloid leukemia, melanoma, 
chronic lymphocytic leukemia and squamous head and neck cancer (CHANG-CLAUDE et al., 2009; 
GANSTER et al., 2009; MITRA et al., 2009; STROM et al., 2010). Of the two homozygous missense 
polymorphisms located in MSH3 (MMR pathway), the rs26279 is associated with increased 
sensitivity to platinum-based chemotherapy in advanced non-small cell lung cancer patients (XU 
et al., 2015). 
In the DSB repair pathway, the homozygous missense variations were found in BARD 1, 
NBS1, and PARP4. The rs1805794 (p.Glu185Gln) of NBS1 is associated with increased risk for 
urinary system cancer, especially for bladder cancer (ZHANG et al., 2014), while the functional 
consequences of the rs1050112 (p.Pro1328Thr), rs13428 (p.Gly1280Arg) and rs7571 of PARP4 
as well as of the rs2070094 (p.Val507Met) of BARD1 are still unknown. The significance of these 
findings is not known yet but may be important for future testing and improvement of the 
diagnosis and outcomes in patients with FA.  
Considering the genes involved in the cell cycle control and apoptosis, the homozygous 
missense variations were found in CDKN1B, TP53 and TP53BP1. The p53 protein is essential for 
regulating different cellular processes such as DNA repair, cell cycle arrest and apoptosis and 
therefore, has a crucial role in maintaining the genetic integrity of the cells (RILEY et al., 2008). 
The functional SNPs located in TP53 are confirmed to affect the p53 signaling pathway 
(GROCHOLA et al., 2010). The rs1042522 (p.Pro72Arg) of TP53 at homozygous state was found in 
two of our patients, while the rest of them were heterozygotes. It has been shown that 72Arg 
variant has a stronger ability to induce apoptosis then 72Pro variant. In other words, 72Arg is 
more efficiently translocated to the mitochondria, where it interacts with proapoptotic proteins 
such as GRP75 and Hsp60, consequently triggering apoptosis (DUMONT et al., 2003). These 
results are in accordance with our previous investigation of FA patients describing the elevated 
level of leukocyte apoptosis either occurring spontaneously or induced by ionizing radiation 
(PETROVIC et al., 2013). Additionally, the report of Litviakov and coworkers (LITVIAKOV et al., 
2010) has shown that 72Arg variant is coupled with higher frequency of aberrant cells and 
chromatid breaks in comparison to individuals with Pro/Pro genotypes. This polymorphism is 
also associated with high risk of diabetes II and acute lymphoblast leukemia (GAULTON et al., 
2008; DO et al., 2009). As for the other two found polymorphisms, the rs34330 of CDKN1B is 
reported to have an association with breast cancer (DRIVER et al., 2008), while the rs560191 
(p.Asp353Glu) of TP53BP1 is associated with a risk of lung cancer (TRUONG et al., 2010). 
As previously stated, the homozygous synonymous nucleotide changes were found in BARD1, 
MSH6, NBS1, RAD54B, CCND1 and GRTH/Ddx25. The literature data provide the evidence that 
synonymous mutations are “silent” with respect to protein sequence but are not always “silent” 
regarding protein function (GINGOLD and PILPEL, 2011). Synonymous SNPs could influence 
protein function affecting mRNA secondary structure and stability consequently reducing protein 
expression (NACKLEY et al., 2006). In other words, “silent” changes may possibly affect the 
mRNA translation (DRUMMOND and WILKE, 2008), folding (GOODMAN et al., 2013) and splicing 
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(PARMLEY et al., 2006), or, through translational pausing, a protein folding (ZHOU et al., 2013). 
Silent mutations are proven to contribute to human cancer (SUPEK et al., 2014). 
 In this study, the thirteen homozygous variants were found in the non-coding regions of 
the genes tested. Several studies provided evidence that SNPs located in the non-coding DNA, 
especially in intronic gene regions near the exon/intron boundaries, could inactivate pre-mRNA 
splice sites consequently affecting gene expression (LOMELIN et al., 2010; VOGELSTEIN et al., 
2013), or could activate cryptic splice sites leading to exonization (WANG and COOPER, 2007). 
Furthermore, the presence of SNPs in the 3`-UTR of selected genes could modify the binding 
with specific microRNAs (miRNAs) (NACCARATI et al., 2012). It has been reported that one of 
the key mechanisms of gene expression control is a post-transcriptional gene regulation by 
miRNAs which interact with the 3`-UTR of target mRNAs inducing their degradation or 
inhibition of their translation, thus silencing gene expression (BARTEK and LUKAS, 2007; 
FILIPOWICZ et al., 2008). Therefore, the SNPs could alter the miRNA–mRNA interaction 
consequently inducing the increase or decrease of protein translation (DUAN et al., 2009). In 
addition, the sequence changes in the 5´ -UTR regions of mRNAs can influence translation 
regulation (WARD and KELLIS, 2012). 
There are many association studies providing the linkage between SNPs in non-coding regions of 
candidate genes and cancer propensity.  As for the homozygous polymorphisms detected in our 
patients, the intronic rs3730849 of LIG1, the 3`-UTR rs1052536 of LIG3 and the intronic 
rs3212948 of ERCC1 are associated with a risk of lung cancer (LANDI et al., 2006; MA et al., 
2007). Similarly, the 5`-UTR variant rs1800975 of XPA is associated with lung cancer risk and 
also with squamous cell carcinoma (Lou et al, 2014). In GADD45A, an intronic rs532446 was 
reported to possess a functional role in acute lung injury (MITRA et al., 2014).  The 5`-UTR 
rs1799943 of BRCA2 is associated with breast cancer susceptibility (SAPKOTA et al., 2013). The 
3`-UTR rs11226 located in RAD52 is reported to has a significant association with 
myelodysplastic syndrome (BELICKOVA et al., 2013). The intronic rs1799796 of XRCC3 is 
associated with ovarian cancer risk (YUAN et al., 2014), while the intronic rs1805377 of XRCC4 is 
associated with an increased risk of glioma development (ZHAO et al., 2013). In addition, the 
intronic variant rs664677 of ATM may play an important role in the development of thyroid 
cancer (SONG et al., 2015) while the 3`-UTR rs678653 located in CCND1 is associated with oral 
cancer (TSAI et al., 2011). Regarding the intronic rs1805403 of PARP1 as well as the 5`-UTR 
rs3732974 located in FANCD2,  the clinical significance of these substitutions has not yet been 
elucidated. 
Investigation of the relatively large number of SNPs, as in the current report, probably 
diminishes the significance of findings; therefore, many of the SNPs assessed (e.g. 
polymorphisms located in ATM, APEX APE 1, XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, 
CDKN1B, TP53, TP53BP1) should be considered as promising candidates for further 
investigation in larger cohort. In addition, since Fanconi anemia is a genetically heterogeneous 
disease, the future investigation should also encompass the SNPs located in other genes that are 
proven to contribute to FA condition i.e., genes involved in bioenergetic pathways, antioxidant 
activities, response to stress and metal-chelating proteins, inflammation-related cytokines and also 
in some selected DNA repair genes such as type II DNA topoisomerase (PAGANO et al., 2013). 
The present report, although descriptive in its nature, may serve as a source for further studies, 
which may confirm the use of SNPs as predictive and prognostic biomarkers to individualize 
therapy of FA patients on genetic basis. 
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Izvod 
Fankonijeva anemija (FA) je genetički heterogeno oboljenje koje se manifestuje progresivnom 
pancitopenijom, razvojnim abnormalnostima i predispozicijom ka razvoju kancera. Nezavisno od 
mutacija u FANC genima koje su direktni uzročnici bolesti, identifikacija varijacija u DNK, 
naročito pojedinačnih nukleotidnih polimorfizama u odabranim genima, može omogućiti 
individualizaciju pristupa svakom pacijentu i poboljšati prognozu bolesti. U ovom istraživanju, 
ispitali smo 95 pojedinačnih nukleotidnih izmena lociranih u 52 ključna gena uključena u bazni 
ekscizioni reper, nukleotidni ekscizioni reper,“ mismatch“ reper, reper dvolančanih prekida DNK, 
kao i u nekoliko gena odgovornih za kontrolu ćelijskog ciklusa i apoptoze. Istraživanjem su 
obuhvaćena pet FA-D2 pacijenta i jedan FA-A pacijent, a genotipizacija polimorfizama  je 
izvršena pomoću DNK reper čipa (Asper Biotech). Proučavani su sinonimni (n=10) i nesinonimni 
(“missense“)  polimorfizmi (n=52), kao i polimorfizmi u nekodirajućim regionima genoma 
(introni i 5‘ i 3’ netranslatorni regioni) (n=33). Rezultati našeg istraživanja pokazuju da se 
pacijenti međusobno razlikuju po tipu i po broju nukleotidnih polimorfizama i istovremeno 
ukazuju na potrebu daljeg ispitivanja polimorfizama lociranih u genima ATM, APEX APE 1, 
XRCC1, ERCC2, MSH3, PARP4, NBS1, BARD1, CDKN1B, TP53 and TP53BP,1 na većem broju 
pacijenata,  što bi omogućilo bolji uvid u kliničku sliku bolesti. Pored toga, pokazano je da 
pojedinačni nukleotidni polimorfizmi mogu imati značajnu ulogu u predikciji kancera kod FA 
pacijenata, kao i u proceni efikasnosti i toksičnosti različitih vidova terapije.  
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